NEW YORK |
(Reuters) - Medical technology provider Cognoptix, which is developing a test for early detection of Alzheimer's Disease, is discussing putting itself up for sale, a person familiar with the situation told Reuters.
The Acton, Massachusetts-based company is working on a test that would detect Alzheimer's Disease in a patient through a scan of the eyes.
Since the company is privately held, it is unclear how much it would be worth in a sale.
Cognoptix has tapped Milwaukee-based Robert W. Baird & Co to help with its discussions and handle a sale process if it goes that route, said the source, who asked to remain anonymous because the situation is confidential.
Calls and e-mails to Baird and Cognoptix were not returned.
On Monday, Cognoptix released data from a multi-site trial that showed its SAPPHIRE II eye test was able to differentiate Alzheimer's patients from healthy volunteers in a majority of cases.
(Reporting by Jessica Toonkel; Editing by John Wallace)
0 comments:
Post a Comment